BioCryst Pharmaceuticals, Inc. (BCRX)

NASDAQ: BCRX · IEX Real-Time Price · USD

4.210

-0.170 (-3.88%)

At close: Apr 24, 2024, 4:00 PM

4.340

+0.130 (3.09%)

Pre-market: Apr 25, 2024, 9:12 AM EDT

BioCryst Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1994
Net Income	-226.54	-247.12	-184.06	-182.81	-108.9	-101.25	-65.78	-55.14	-43.02	-45.19	Upgrade
Depreciation & Amortization	1.66	1.44	0.78	0.75	0.72	0.77	0.7	0.48	0.18	0.18	Upgrade
Share-Based Compensation	55.62	44.7	34.64	14.79	17.72	9.4	12.62	8.49	9.71	10.18	Upgrade
Other Operating Activities	74.13	39.13	6.49	32.16	0.87	-1.48	11.31	-7.26	20.02	-3.72	Upgrade
Operating Cash Flow	-95.14	-161.85	-142.16	-135.11	-89.58	-92.57	-41.14	-53.44	-13.12	-38.55	Upgrade
Capital Expenditures	-2.17	-1.35	-2.39	-0.51	-0.34	-0.37	-0.32	-5.27	-5.12	-0.11	Upgrade
Change in Investments	-129.33	-126.89	18.19	-6.34	78.28	5.13	-64.33	28.55	-11.42	-39.88	Upgrade
Other Investing Activities	-	-	-	-	-	-	-	-	-1.46	0	Upgrade
Investing Cash Flow	-131.5	-128.24	15.8	-6.86	77.93	4.77	-64.64	23.27	-18	-39.98	Upgrade
Share Issuance / Repurchase	8.68	14.96	65.79	95.73	59.74	56.25	135.58	0.32	5.48	111.91	Upgrade
Debt Issued / Paid	25.98	73.07	293.87	190.05	19.48	6.25	0.12	22.99	0	0	Upgrade
Other Financing Activities	-2.17	-	-	14.82	19.88	-	-	-	-	-	Upgrade
Financing Cash Flow	32.49	88.03	359.67	300.59	99.1	62.5	135.7	23.3	5.48	111.91	Upgrade
Exchange Rate Effect	0.36	0.57	0.07	0	0	0	0	0	0	0	Upgrade
Net Cash Flow	-193.79	-201.5	233.39	158.63	87.45	-25.29	29.92	-6.86	-25.64	33.38	Upgrade
Free Cash Flow	-97.31	-163.2	-144.54	-135.62	-89.93	-92.93	-41.46	-58.71	-18.24	-38.66	Upgrade
Free Cash Flow Margin	-29.36%	-60.26%	-91.97%	-761.41%	-184.14%	-449.96%	-164.61%	-222.79%	-37.79%	-284.08%	Upgrade
Free Cash Flow Per Share	-0.51	-0.88	-0.81	-0.81	-0.78	-0.90	-0.49	-0.80	-0.25	-0.58	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).